Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 4Unknown 2Completed 2Withdrawn 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 88INDUSTRY 6OTHER_GOV 4NETWORK 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Gastrointestinal 2Gynecologic 1

Conditions

Uterine Cervical Neoplasms 1Esophageal Neoplasms 1Efficacy, Team 1Colorectal Neoplasms 1

Interventions

Drug Therapy 10pembrolizumab 9Bevacizumab 9Radiotherapy 8Cyclophosphamide 8Carboplatin 8Oxaliplatin 7tislelizumab 6Surgical Procedures, Operative 6Docetaxel 6Cisplatin 6Capecitabine 6Paclitaxel 5Nivolumab 5Fluorouracil 5Control Groups 5fludarabine 4Immune Checkpoint Inhibitors 4Gemcitabine 4Endoscopic Mucosal Resection 4sintilimab 3Trastuzumab 3Pemetrexed 3Neoadjuvant Therapy 3Leucovorin 3Laparoscopy 3Irinotecan 3Injections 3Hematologic Tests 3HMPL-013 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × OTHER_GOV × Immune Checkpoint Inhibitors × Clear all
NCT05937438 2025-01-29

Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma

Anhui Provincial Hospital

Phase 1/2 Recruiting
70 enrolled
Gastrointestinal

Esophageal Neoplasms

NCT06693440 2024-11-18

The Immune Assessment of PD-1 Antibody Therapy in Tumor

Henan Cancer Hospital

Recruiting
3,000 enrolled

Efficacy, Team

NCT06455072 2024-06-12

Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer

Fujian Cancer Hospital

Phase 2 Recruiting
37 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT06321081 2024-03-20

ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC

Beijing Hospital

Phase 2 Recruiting
60 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡